Perhaps repeated PLD1 inhibition at 1 mg/kg may be optimal in modulating glutamatergic neurotransmission to preserve synaptic functionality, thereby altering the homeostasis enough to resist cognitive decline without affecting the physiological functionality associated with Aβ and tau. The gene discussed is PLD1; the disease is Mental deterioration.